Economic Evaluation of Adding Dapagliflozin to Standard Care in the Treatment of Chronic Kidney Disease: a Systematic Review

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2024 Dec 18

PMID 39695416

Authors

Lu Wang

Yinglin Wang

Quan Zhao

Affiliations

Soon will be listed here.

Abstract

Introduction: Chronic kidney disease is a significant public health issue. Dapagliflozin has been shown to improve the quality of life for patients with chronic kidney disease. This review aimed to systematically assess the cost-effectiveness of adding dapagliflozin to standard care compared with standard care alone for treating chronic kidney disease.

Methods: The relevant studies were searched in PubMed, Web of Science, Scopus, Embase, and Cochrane from the inception date to June 1, 2024. The titles, abstracts, and full texts were independently evaluated and screened by two authors. Additionally, the economic evaluation studies were assessed independently by two authors using the consolidated health economic evaluation reporting standards checklist.

Results: 14 studies were included which were about the economic evaluations of adding dapagliflozin in the treatment of chronic kidney disease. The minimum consolidated health economic evaluation reporting standards score for the studies was 0.77, indicating very good quality. Adding dapagliflozin to the standard of care would be more effective and cost-saving in Mexico, Malaysia, Canada, Thailand, and China. The highest incremental cost-effectiveness ratio of dapagliflozin ($67962.75/QALY) originated from the USA. According to the available studies, adding dapagliflozin to standard of care for the treatment of chronic kidney disease is considered cost-effectiveness from both the healthcare system and the payer's perspective.

Conclusion: Adding dapagliflozin to standard care in the treatment of chronic kidney disease is cost-effective from both the healthcare system and the payer's perspective in well-developed countries.

References

Nerich V, Saing S, Gamper E, Kemmler G, Daval F, Pivot X . Cost-utility analyses of drug therapies in breast cancer: a systematic review. Breast Cancer Res Treat. 2016; 159(3):407-24. DOI: 10.1007/s10549-016-3924-7. View

Wang L, Xu X, Zhang M, Hu C, Zhang X, Li C . Prevalence of Chronic Kidney Disease in China: Results From the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Intern Med. 2023; 183(4):298-310. PMC: 9941971. DOI: 10.1001/jamainternmed.2022.6817. View

Nguyen B, Mital S, Bugden S, Nguyen H . Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes. Diabetes Obes Metab. 2023; 25(10):3030-3039. DOI: 10.1111/dom.15201. View

Bello A, Okpechi I, Levin A, Ye F, Damster S, Arruebo S . An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024; 12(3):e382-e395. DOI: 10.1016/S2214-109X(23)00570-3. View

Xue Y, Zou H, Ruan Z, Chen X, Lai Y, Yao D . Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature. Front Endocrinol (Lausanne). 2023; 14:1254398. PMC: 10658190. DOI: 10.3389/fendo.2023.1254398. View

Heerspink H, Stefansson B, Chertow G, Correa-Rotter R, Greene T, Hou F . Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020; 35(2):274-282. PMC: 7005525. DOI: 10.1093/ndt/gfz290. View

Rezapour A, Souresrafil A, Shamsaei M, Barzegar M, Tashakori-Miyanroudi M, Ketabchi E . Economic evaluation of ferric carboxymaltose compared with placebo in iron-deficient patients with heart failure: a systematic review. Int J Clin Pharm. 2023; 45(3):566-576. DOI: 10.1007/s11096-022-01532-2. View

Vareesangthip K, Deerochanawong C, Thongsuk D, Pojchaijongdee N, Permsuwan U . Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand. Adv Ther. 2022; 39(3):1279-1292. PMC: 8918172. DOI: 10.1007/s12325-021-02037-6. View

Iimuro S, Kaneko T, Ohashi Y, Watanabe T, Nitta K, Akizawa T . Analysis of 2897 hospitalization events for patients with chronic kidney disease: results from CKD-JAC study. Clin Exp Nephrol. 2019; 23(7):956-968. PMC: 6555784. DOI: 10.1007/s10157-019-01730-9. View

10.

McEwan P, Davis J, Gabb P, Wheeler D, Rossing P, Chertow G . Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial. Clin Kidney J. 2024; 17(2):sfae025. PMC: 10883141. DOI: 10.1093/ckj/sfae025. View

11.

Lim S, Lee S . Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia. PLoS One. 2024; 19(3):e0296067. PMC: 10917287. DOI: 10.1371/journal.pone.0296067. View

12.

McEwan P, Darlington O, Miller R, McMurray J, Wheeler D, Heerspink H . Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022; 17(12):1730-1741. PMC: 9718008. DOI: 10.2215/CJN.03790322. View

13.

Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View

14.

Schmucker C, Blumle A, Schell L, Schwarzer G, Oeller P, Cabrera L . Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research. PLoS One. 2017; 12(4):e0176210. PMC: 5404772. DOI: 10.1371/journal.pone.0176210. View

15.

Tisdale R, Cusick M, Aluri K, Handley T, Cummings Joyner A, Salomon J . Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. J Gen Intern Med. 2022; 37(13):3380-3387. PMC: 9551016. DOI: 10.1007/s11606-021-07311-5. View

16.

Raz I, Mosenzon O, Bonaca M, Cahn A, Kato E, Silverman M . DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes Obes Metab. 2018; 20(5):1102-1110. DOI: 10.1111/dom.13217. View

17.

Luyckx V, Tonelli M, Stanifer J . The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018; 96(6):414-422D. PMC: 5996218. DOI: 10.2471/BLT.17.206441. View

18.

Chen T, Hoenig M, Nitsch D, Grams M . Advances in the management of chronic kidney disease. BMJ. 2023; 383:e074216. DOI: 10.1136/bmj-2022-074216. View

19.

Loperto I, Simonetti A, Nardone A, Triassi M . Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence. Hum Vaccin Immunother. 2019; 15(5):1035-1047. PMC: 6605847. DOI: 10.1080/21645515.2019.1578597. View

20.

Kodera S, Morita H, Nishi H, Takeda N, Ando J, Komuro I . Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan. Circ J. 2022; 86(12):2021-2028. DOI: 10.1253/circj.CJ-22-0086. View